S. 1954

Status: Reported

Biosimilar Red Tape Elimination Act

Biosimilar Red Tape Elimination Act

Sponsored by Mike Lee (Republican-UT)

Topics

Cosponsors

5

Actions

6

Roll calls

0

Amendments

0

Related bills

1

Actions

Jul 27, 2026 · Library of Congress

Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

Jul 27, 2026 · Senate

Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

Jul 27, 2026 · Senate

Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.

Jun 17, 2026 · Senate

Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

Jun 4, 2025 · Library of Congress

Introduced in Senate

Jun 4, 2025 · Senate

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest activity

July 2026

Lobbying reported · Families USA Foundation · Jul 30

Families USA Foundation reported 2nd Quarter (Apr 1 - June 30) lobbying for Families USA Foundation — $9,000

BillsH.R. 6248 H.R. 7973 H.R. 8317 H.R. 9392 H.R. 9397 H.R. 9644 H.R. 9831 H.R. 9832 H.R. 9833 H.Res. 1268 S. 527 S. 958 S. 1040 S. 1041 S. 1096 S. 1954 S. 2355 S. 3014

Bill reported · Jul 27Reported

Biosimilar Red Tape Elimination Act

Bill reported · Jul 27Reported

Biosimilar Red Tape Elimination Act

Lobbying reported · Whitmer & Worrall · Jul 22

Whitmer & Worrall reported 2nd Quarter (Apr 1 - June 30) lobbying for Campaign For Sustainable Drug Pricing (csrxp) — $50,000

BillsH.R. 1262 H.R. 1843 H.R. 3160 H.R. 3269 H.R. 3789 H.R. 4570 H.R. 5526 H.R. 6485 S. 43 S. 1032 S. 1040 S. 1041 S. 1096 S. 1414 S. 1546 S. 1954 S. 2658 S. 3014

Lobbying reported · National Taxpayers Union · Jul 21

National Taxpayers Union reported 2nd Quarter (Apr 1 - June 30) lobbying for National Taxpayers Union — $30,000

Lobbying reported · Covington & Burling · Jul 20

Covington & Burling reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research Manufacturers Of America — $220,000

BillsH.R. 2715 H.R. 5526 H.R. 7953 H.R. 8646 S. 1414 S. 1954 S. 2658 S. 3014

Lobbying reported · American College of Rheumatology · Jul 20

American College of Rheumatology reported 2nd Quarter (Apr 1 - June 30) lobbying for American College of Rheumatology — $180,000

Lobbying reported · America's Health Insurance Plans (ahip) · Jul 20

America's Health Insurance Plans (ahip) reported 2nd Quarter (Apr 1 - June 30) lobbying for America's Health Insurance Plans (ahip) — $3,010,000

BillsH.R. 1 H.R. 247 H.R. 379 H.R. 584 H.R. 608 H.R. 610 H.R. 842 H.R. 935 H.R. 950 H.R. 957 H.R. 1096 H.R. 1117 H.R. 1157 H.R. 1162 H.R. 1397 H.R. 1403 H.R. 1523 H.R. 1614 H.R. 1627 H.R. 1775 H.R. 1776 H.R. 1805 H.R. 1867 H.R. 1899 H.R. 1924 H.R. 2013 H.R. 2045 H.R. 2049 H.R. 2079 H.R. 2199 H.R. 2309 H.R. 2433 H.R. 2450 H.R. 2528 H.R. 2533 H.R. 2553 H.R. 2554 H.R. 2571 H.R. 2586 H.R. 2610 H.R. 2636 H.R. 2741 H.R. 3000 H.R. 3023 H.R. 3069 H.R. 3415 H.R. 3493 H.R. 3527 H.R. 3546 H.R. 3701 H.R. 3789 H.R. 3808 H.R. 4093 H.R. 4206 H.R. 4231 H.R. 4313 H.R. 4317 H.R. 4406 H.R. 4559 H.R. 4605 H.R. 4623 H.R. 4641 H.R. 4710 H.R. 5081 H.R. 5145 H.R. 5243 H.R. 5281 H.R. 5371 H.R. 5509 H.R. 5526 H.R. 5582 H.R. 5584 H.R. 6010 H.R. 6232 H.R. 6248 H.R. 6255 H.R. 6361 H.R. 6703 H.R. 6951 H.R. 6974 H.R. 7023 H.R. 7064 H.R. 7164 H.R. 7189 H.R. 7409 H.R. 7537 H.R. 7727 H.R. 7778 H.R. 7787 H.R. 7790 H.R. 7803 H.R. 7837 H.R. 7871 H.R. 8270 H.R. 8375 H.R. 8377 H.R. 8684 H.R. 8779 H.R. 8875 H.R. 9393 H.R. 9504 S. 339 S. 483 S. 526 S. 529 S. 652 S. 717 S. 729 S. 752 S. 864 S. 882 S. 891 S. 931 S. 939 S. 976 S. 1040 S. 1041 S. 1056 S. 1082 S. 1096 S. 1227 S. 1261 S. 1414 S. 1637 S. 1753 S. 1816 S. 1818 S. 1847 S. 1954 S. 1973 S. 2237 S. 2289 S. 2345 S. 2355 S. 2356 S. 2497 S. 2556 S. 2620 S. 2658 S. 2709 S. 2903 S. 3014 S. 3599 S. 3642 S. 3690 S. 3727 S. 3729 S. 3750 S. 3751 S. 3762 S. 3822 S. 3829 S. 3834 S. 3848 S. 3886 S. 3990 S. 4189 S. 4332 S. 4355 S. 4384 S. 4509 S. 4512

Lobbying reported · Association for Accessible Medicines · Jul 20

Association for Accessible Medicines reported 2nd Quarter (Apr 1 - June 30) lobbying for Association for Accessible Medicines — $870,000

BillsH.R. 3160 H.R. 3269 H.R. 5526 H.R. 5811 H.R. 6485 H.R. 7148 H.R. 8269 H.R. 8339 S. 43 S. 1041 S. 1096 S. 1414 S. 1546 S. 1553 S. 1954 S. 2658 S. 3469 S. 3788

Lobbying reported · Kaiser Foundation Health Plan · Jul 20

Kaiser Foundation Health Plan reported 2nd Quarter (Apr 1 - June 30) lobbying for Kaiser Foundation Health Plan — $530,000

BillsH.R. 3269 H.R. 3514 H.R. 5429 H.R. 5526 H.R. 5582 H.R. 6248 H.R. 6644 H.R. 7148 H.R. 8800 H.R. 9393 H.R. 9504 S. 43 S. 1414 S. 1816 S. 1954 S. 2355 S. 2620 S. 2780 S. 3014 S. 3822 S. 4027 S. 4784

Lobbying reported · The Nickles Group · Jul 20

The Nickles Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $60,000

BillsH.R. 1 S. 1954 S. 2658 S. 3014 S. 3788

Lobbying reported · Blue Cross And Blue Shield Of Florida · Jul 20

Blue Cross And Blue Shield Of Florida reported 2nd Quarter (Apr 1 - June 30) lobbying for Blue Cross And Blue Shield Of Florida — $80,000

Lobbying reported · Fresenius Kabi USA · Jul 20

Fresenius Kabi USA reported 2nd Quarter (Apr 1 - June 30) lobbying for Fresenius Kabi USA — $580,000

BillsH.R. 3269 H.R. 5526 S. 1414 S. 1954 S. 2658

Lobbying reported · Amgen · Jul 20

Amgen reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $2,440,000

Lobbying reported · Johnson & Johnson Services · Jul 20

Johnson & Johnson Services reported 2nd Quarter (Apr 1 - June 30) lobbying for Johnson & Johnson Services — $1,440,000

Lobbying reported · Pharmaceutical Research and Manufacturers of America (PhRMA) · Jul 20

Pharmaceutical Research and Manufacturers of America (PhRMA) reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $7,360,000

Lobbying reported · Vizient · Jul 20

Vizient reported 2nd Quarter (Apr 1 - June 30) lobbying for Vizient — $320,000

BillsH.R. 2213 H.R. 3178 H.R. 3514 H.R. 3890 H.R. 4191 H.R. 4731 H.R. 8339 S. 1784 S. 1816 S. 1954 S. 2439 S. 2556

Lobbying reported · Small Business & Entrepreneurship Council (SBE Council) · Jul 20

Small Business & Entrepreneurship Council (SBE Council) reported 2nd Quarter (Apr 1 - June 30) lobbying for Small Business & Entrepreneurship Council (SBE Council) — $45,000

Lobbying reported · Avenue Solutions · Jul 20

Avenue Solutions reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $50,000

BillsH.R. 4299 H.R. 5526 S. 1954

Lobbying reported · American Society Of Health-System Pharmacists · Jul 20

American Society Of Health-System Pharmacists reported 2nd Quarter (Apr 1 - June 30) lobbying for American Society Of Health-System Pharmacists — $260,000